141 related articles for article (PubMed ID: 11966641)
41. Photodynamic activity of hypericin in human urinary bladder carcinoma cells.
Kamuhabwa AR; Agostinis P; D'Hallewin MA; Kasran A; de Witte PA
Anticancer Res; 2000; 20(4):2579-84. PubMed ID: 10953329
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of patients with carcinoma in situ of the bladder.
Koss LG
Pathol Annu; 1982; 17 Pt 2():353-9. PubMed ID: 7182757
[No Abstract] [Full Text] [Related]
43. Fluorescence cystoscopy and bladder surveillance.
Joudi FN; Konety BR
Curr Opin Urol; 2004 Sep; 14(5):265-70. PubMed ID: 15300146
[TBL] [Abstract][Full Text] [Related]
44. In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors.
Zupkó I; Kamuhabwa AR; D'Hallewin MA; Baert L; De Witte PA
Int J Oncol; 2001 May; 18(5):1099-105. PubMed ID: 11295062
[TBL] [Abstract][Full Text] [Related]
45. Permeation of hypericin in spheroids composed of different grade transitional cell carcinoma cell lines and normal human urothelial cells.
Huygens A; Kamuhabwa AR; Roskams T; VAN Cleynenbreugel B; VAN Poppel H; de Witte PA
J Urol; 2005 Jul; 174(1):69-72. PubMed ID: 15947580
[TBL] [Abstract][Full Text] [Related]
46. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder.
Lerner SP; Liu H; Wu MF; Thomas YK; Witjes JA
Urol Oncol; 2012; 30(3):285-9. PubMed ID: 21396840
[TBL] [Abstract][Full Text] [Related]
47. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
[TBL] [Abstract][Full Text] [Related]
48. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
49. [Intravesical instillations of BCG and bladder carcinoma in situ].
Haab F; Dauge MC; Delmas V; Boccon-Gibod L
Prog Urol; 1993 Dec; 3(6):988-94; discussion 992-3. PubMed ID: 8305942
[TBL] [Abstract][Full Text] [Related]
50. [The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder].
Jichlinski P; Wagniéres G; Forrer M; Mizeret J; Guillou L; Schmidlin F; Graber P; Van den Bergh H; Leisinger HJ
Ann Urol (Paris); 1997; 31(1):43-8. PubMed ID: 9157821
[TBL] [Abstract][Full Text] [Related]
51. Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guérin immunotherapy.
Kim SJ; You D; Jeong IG; Song C; Hong B; Kim CS; Ahn H; Hong JH
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2131-2140. PubMed ID: 31227894
[TBL] [Abstract][Full Text] [Related]
52. Fluorescence guided optical coherence tomography for the diagnosis of early bladder cancer in a rat model.
Wang ZG; Durand DB; Schoenberg M; Pan YT
J Urol; 2005 Dec; 174(6):2376-81. PubMed ID: 16280851
[TBL] [Abstract][Full Text] [Related]
53. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid.
Kriegmair M; Baumgartner R; Knuechel R; Steinbach P; Ehsan A; Lumper W; Hofstädter F; Hofstetter A
Urology; 1994 Dec; 44(6):836-41. PubMed ID: 7985312
[TBL] [Abstract][Full Text] [Related]
54. Detection of bladder carcinoma in females by flow cytometry and cytology.
Hermansen DK; Badalament RA; Fair WR; Kimmel M; Whitmore WF; Melamed MR
Cytometry; 1989 Nov; 10(6):739-42. PubMed ID: 2582965
[TBL] [Abstract][Full Text] [Related]
55. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.
Mian C; Lodde M; Comploj E; Palermo S; Mian M; Maier K; Pycha A
Anticancer Res; 2005; 25(5):3641-4. PubMed ID: 16101194
[TBL] [Abstract][Full Text] [Related]
56. Autofluorescence imaging to optimize 5-ALA-induced fluorescence endoscopy of bladder carcinoma.
Frimberger D; Zaak D; Stepp H; Knüchel R; Baumgartner R; Schneede P; Schmeller N; Hofstetter A
Urology; 2001 Sep; 58(3):372-5. PubMed ID: 11549483
[TBL] [Abstract][Full Text] [Related]
57. Influence of the glycosaminoglycan layer on the permeation of hypericin in rat bladders in vivo.
Huygens A; Crnolatac I; Maes J; Van Cleynenbreugel B; Van Poppel H; Roskams T; de Witte PA
BJU Int; 2007 Nov; 100(5):1176-81. PubMed ID: 17868424
[TBL] [Abstract][Full Text] [Related]
58. Fluorescence detection of bladder cancer using urine cytology.
Fu CY; Ng BK; Razul SG; Chin WW; Tan PH; Lau WK; Olivo M
Int J Oncol; 2007 Sep; 31(3):525-30. PubMed ID: 17671678
[TBL] [Abstract][Full Text] [Related]
59. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy.
Grimbergen MC; van Swol CF; Jonges TG; Boon TA; van Moorselaar RJ
Eur Urol; 2003 Jul; 44(1):51-6. PubMed ID: 12814675
[TBL] [Abstract][Full Text] [Related]
60. Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305).
Mostafid H; Bunce C;
BJU Int; 2009 Oct; 104(7):889-90. PubMed ID: 19549121
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
